Comment on "Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity"

Clin Breast Cancer. 2020 Oct;20(5):e623-e624. doi: 10.1016/j.clbc.2020.04.014. Epub 2020 May 6.

Authors

Maria Carmen De Santis¹, Eliana La Rocca², Angelo Vitullo², Icro Meattini³, Lorenzo Livi³

Affiliations

¹ Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: mariacarmen.desantis@istitutotumori.mi.it.
² Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
³ Radiation Oncology Unit - Oncology Department, University of Florence - Azienda Ospedaliero Universitaria Careggi, Florence, Italy.

PMID: 32482524
DOI: 10.1016/j.clbc.2020.04.014

No abstract available

Publication types

Letter
Comment

MeSH terms

Breast Neoplasms* / drug therapy
Breast Neoplasms* / radiotherapy
Capecitabine / adverse effects
Chemotherapy, Adjuvant
Feasibility Studies
Humans
Radiotherapy, Adjuvant / adverse effects

Substances

Capecitabine